anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a clathrate compound stable in living body, having high selectivity to hepatocyte and useful as a new DDS preparation for the treatment of hepatic diseases acting on hepatic tissue as the target. CONSTITUTION:The clathrate compound of (A) a fat-soluble treating agent for hepatic diseases such as anthracycline-type antitumor agent (e.g. daunorubicin), an oligo-ene agent for treating hepatic diseases (e.g. amphotericin), a pyrimidine-type antitumor agent (e.g. fluorouracil) and a beta-lactam antibiotic substance (e.g. tamoxilline) and (B) a polyvinylbenzyl lactonamide (PVLA) having the recurring unit of formula. The clathrate compound can be produced by adding a solution of the hepatic disease treating agent having a concentration of 1.0X10<-5> to 7.0X10<-5> to a PVLA solution having a concentration of 1.00X10<-3> to 7.0X10<-3> and stirring the mixture or by adding a small amount of water to PVLA to form a paste, adding the hepatic disease treating agent to the paste and kneading the mixture with a mixer.
To date the standard non-surgical treatment strategy for treating un-ruptured intracranial aneurysms is the use of either coils or self-expandable stents. The flow diverter stent concept is based upon the hemodynamic exclusion of the aneurysm sac, without coils being eventually placed within the sac. The primary objective of this post-market clinical investigation is to demonstrate that when using the CE-marked, commercially available SILK Artery Reconstruction Device in the indication for which it is approved, notably for the treatment (occlusion) of intracranial aneurysms, the anatomical results are superior compared to standard treatment with commercially available intracranial coils (used with eventual balloon remodeling and/or stents when necessary). It is a prospective, randomized, unblinded, multi-center post-market clinical investigation. The patient population comprises a maximum of 160 subjects with at least one documented untreated, unruptured intracranial aneurysm suitable for occlusion with an intracranial device. Subject enrollment will require a maximum of 18 months. Enrolled subjects will be followed for 12 months after treatment.
PURPOSE:The titled pharmaceutical containing an ester of alpha-linolenic acid as an active constituent. CONSTITUTION:An antiarterioscherotic pharmaceutical containing an ester of alpha-linolenic acid, e.g. triglyceride containing alpha-linolenic acid as a component or ethyl alpha-linolenate, as an active constituent. The dose thereof is 1-30g/man/day, preferably 4-10g/man/day administered once - in divided 3 portions. The pharmaceutical can be administered by an optional method, e.g. intravenous injection, and a mixture or combined drug thereof with other components or pharmaceuticals may be used. In use as the mixture or combined drug, the amount of the above-mentioned active constituent is preferably 1-10wt/vol%. In case the above-mentioned pharmaceutical is used in the form of a fat transfusion solution, 0-95wt/vol%, based on the fat, above-mentioned ester of the alpha- linolenic acid or further purified soybean oil or purified safflower oil, may be incorporated therein for use.
PROBLEM TO BE SOLVED: To provide molded articles for dental use and dental resin materials suitable for the environment in the oral cavity of a patient while ensuring the adhesive strength with other kinds of resins.SOLUTION: A molded article for dental use has a given shape used in the oral cavity and has impact-resistant polystyrene, titanium oxide, titan yellow, iron oxide, and zinc stearate. The impact-resistant polystyrene is contained as a main component at the ratio of 99% or more. The titanium oxide has a weight ratio to the impact-resistant polystyrene of 0.001 to 0.09%. The titan yellow has a weight ratio to the impact-resistant polystyrene of 0.001 to 0.09%. The iron oxide has a weight ratio to the impact-resistant polystyrene of 0.0001 to 0.01%. The zinc stearate has a weight ratio to the impact-resistant polystyrene of 0.01 to 0.8%.SELECTED DRAWING: Figure 1
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal interstitial lung disease, with limited therapeutic options available. Impaired autophagy resulting from aberrant TRB3/p62 protein-protein interactions (PPIs) contributes to the progression of IPF. Restoration of autophagy by modulating the TRB3/p62 PPIs has rarely been reported for the treatment of IPF. Herein, peptide nanofibers are developed that specifically bind to TRB3 protein and explored their potential as a therapeutic approach for IPF. By conjugating with the self-assembling fragment (Ac-GFFY), a TRB3-binding peptide motif A2 allows for the formation of nanofibers with a stable α-helix secondary structure. The resulting peptide (Ac-GFFY-A2) nanofibers exhibit specific high-affinity binding to TRB3 protein in saline buffer and better capacity of cellular uptake to A2 peptide. Furthermore, the TRB3-targeting peptide nanofibers efficiently interfere with the aberrant TRB3/p62 PPIs in activated fibroblasts and fibrotic lung tissue of mice, thereby restoring autophagy dysfunction. The TRB3-targeting peptide nanofibers inhibit myofibroblast differentiation, collagen production, and fibroblast migration in vitro is demonstrated, as well as bleomycin-induced pulmonary fibrosis in vivo. This study provides a supramolecular method to modulate PPIs and highlights a promising strategy for treating IPF diseases by restoring autophagy.
Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
Intervention for severe aortic stenosis (AS) has dramatically progressed since the introduction of transcatheter aortic valve replacement (TAVR). Decades ago, controversies existed regarding comparing clinical outcomes between TAVR and surgical aortic valve replacement (SAVR) in various risk profiles. Recently, we discussed the durability of transcatheter heart valves and their lifetime management after aortic valve replacement (AVR). Regarding the management of AS, we discuss the appropriate timing of intervention for severe aortic stenosis, especially in asymptomatic patients. In spite of dramatic progression of intervention for AS, there are no established medications available to prevent or slow the progression of AS at present. Basic research and genome studies have suggested several targets associated with the progression of aortic valve calcification. Randomized controlled trials evaluating the efficacy of medications to prevent AS progression are ongoing, which might lead to new strategies for AS management. In this review, we summarize the current management of AS and the drugs expected to prevent the progression of AS.
The invention relates to a pharmaceutical composition, and discloses an asarin pharmaceutical composition. The asarin pharmaceutical composition comprises the following components in parts by weight: 1 part of asarin, 5 to 15 parts of soybean oil, 2 to 3 parts of phospholipid, 3 to 6 parts of citric acid, 3 to 5 parts of glycerinum, and 1 to 2 parts of cysteine hydrochloride. The invention also discloses a method for processing an asarin injection using the pharmaceutical composition. By adopting the asarin pharmaceutical composition, the solubilization effect of the asarin injection can be improved, and the content stability can be raised. The asarin pharmaceutical composition solution is close to a true solution. The preparation method of the asarin injection is simple and applicable to industrial production.
PROBLEM TO BE SOLVED: To provide a raw material effective in the fields of medicines, health foods, etc., by using laver as a raw material. SOLUTION: This laver enzymolysis product comprises a peptide mixture which is obtained by hydrolyzing laver with pepsin and has a hypotensive action. When the laver as the raw material is preliminarily boiled for >=1 hr before hydrolyzed with the pepsin, and then subjected to the removal of the soup, the hypotensive action is enhanced, and the bitter taste, smell, viscosity, etc., of the laver enzymolysis product are removed. Thereby, the laver enzymolysis product is more useful as the hypotensive agent. The laver enzymolysis product further has effects contributing to health, such as a hypoglycaemic action, a hypocholesterolemic action, and a calcium precipitation-inhibiting action, and can be added to foods to prepare health foods.  When the laver is hydrolyzed with the pepsin and further with an enzyme having a peptidase activity, the product giving a good taste and thereby suitable as a food additive can be obtained.
PURPOSE:To provide a hair tonic cosmetic effective to promote the hair growth, containing natural germanium compound separated or extracted from a plant and effective to improve the nutrient of hair root and promote the growth of hair by supplying sufficient oxygen to the cell of the subcutaneous hair root by topical application. CONSTITUTION:A natural germanium compound is separated or extracted by conventional method from a plant such as polypore, Panax ginseng, hydrangea, comfrey, KASHI (fruit of Terminalia chebula), SANZUKON (root of Sophora subprosarata), nut of water caltrop, BANDAI mushroom, seed of boxthorn, etc. or from a plant applied with an aqueous solution of germanium oxide, germanium dioxide, etc. The germanium compound is added to a hair tonic cosmetic at a concentration of >=20ppm, preferably 20-500ppm. The oxygen consumption in the body can be suppressed by the above compound, and consequently, the cell of the subcutaneous hair root of the applied part is supplied with sufficient oxygen to improve the nutrient of the cell and promote the growth of hair. Furthermore, the compound prevents the falling off of hair, dandruff, itchiness and grey hair, and gives a safe hair tonic cosmetic effective to beauty as well as hair growth.
PROBLEM TO BE SOLVED: To improve the centering of a core of a compression coating tablet.SOLUTION: A pin punch assembly is positioned so as to contact with a top portion of bottom fill powder 19 in a metal mold 17. A roll 13 applies pressure on a protrusion 11 on a pin with a non-punching end of the pin 3 as a fixed position. The pressure compresses a spring 9 so as to project out the pin from a housing, by moving the pin to the housing 1. When the pin moves, an impression or a cup is punched and put in a bottom fill. The size of the impression directly depends on the size of the pin. The depth of the impression directly depends on the height of the protrusion positioned at the top portion of the pin. Next, the pin goes out from the roll, and returns to an original position by action of the spring and a key 5 intercepting the pin at this position.
Gut microbiota regulates various aspects of human physiology by producing metabolites, metabolizing enzymes, and toxins. Many studies have linked microbiota with human health and altered microbiome configurations with the occurrence of several diseases, including cancer. Accumulating evidence suggests that the microbiome can influence the initiation and progression of several cancers. Moreover, some microbiotas of the gut and oral cavity have been reported to infect tumors, initiate metastasis, and promote the spread of cancer to distant organs, thereby influencing the clinical outcome of cancer patients. The gut microbiome has recently been reported to interact with environmental factors such as diet and exposure to environmental toxicants. Exposure to environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs) induces a shift in the gut microbiome metabolic pathways, favoring a proinflammatory microenvironment. In addition, other studies have also correlated cancer incidence with exposure to PAHs. PAHs are known to induce organ carcinogenesis through activating a ligand-activated transcriptional factor termed the aryl hydrocarbon receptor (AhR), which metabolizes PAHs to highly reactive carcinogenic intermediates. However, the crosstalk between AhR and the microbiome in mediating carcinogenesis is poorly reviewed. This review aims to discuss the role of exposure to environmental pollutants and activation of AhR on microbiome-associated cancer progression and explore the underlying molecular mechanisms involved in cancer development.
Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions. The intervention will start on the first day postoperatively. The program may not exceed 30% of maximum heart rate reserve of the patient that will be calculated by the Karvonen formula (Karvonen, Kentala et al., 1957). The exercises will be conducted at the patient's bedside, using light resistance springs representing the lowest possible burden of springs to be used in the Pilates method. The exercises will be performed on the upper limbs alternating between the left and right upper limb and likewise would run with the lower limbs by means of a protocol consists of four exercises until the limit of resistance of the patient or interrupt pre-established criteria.

One set of each exercise with a range of up to two minutes between exercises will be held. In the first three days of intervention 10 repetitions of each exercise and the remaining three days a total of 15 repetitions of each movement will be performed.
Depression is a common disorder among adolescents. If left untreated, it can cause significant disability, illness, and even death. Teens with depression often engage in risky health behaviors, such as smoking, drug and alcohol use, unprotected sex, and unhealthy eating and exercise patterns. By reducing these health risk behaviors, depressed adolescents may be able to avoid negative health consequences and improve their physical and mental health. This study will determine the effectiveness of a health education intervention in reducing risky health behaviors in adolescents with depression.

Participants in this study will be invited to enroll during a visit to a participating primary care clinic. Participants will be randomly assigned to either partake in a health education intervention or receive standard care. Both groups will continue to receive treatment through their primary care clinic. Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors. Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention. The intervention will be tailored to target the specific risky behaviors in which each participant engages. Motivational interviewing will also be used to build positive attitudes to support behavior change. All participants will attend follow-up visits to assess behavior change at Months 6 and 12 following study entry.
Osteoarthritis (OA) is a leading cause of disability. Identifying modifiable mechanisms of poor knee joint health development for disease prevention strategies are critical to improving long-term health. Aberrant mechanical loading has been theorized as a primary risk factor for knee OA. Most studies primarily focus on mechanical mechanisms of excessive joint loading in OA development. However, recent evidence suggests that joint underloading may also play a role. The effects of low loading frequency assessed via daily steps in real world settings on knee joint health is an understudied parameter of aberrant mechanical loading in individuals at risk for OA. Individuals with anterior cruciate ligament (ACL) injury who undergo ACL reconstruction (ACLR) surgery are a representative population to assess the effects of low loading frequency on knee joint health because they are at elevated risk for posttraumatic OA development and demonstrate low daily steps compared to uninjured individuals. Therefore, the overall study objective is to determine the mechanistic links between joint loading frequency and comprehensive magnetic resonance imaging (MRI) measures of knee joint cartilage health in individuals post-ACLR. The central hypothesis is that individuals post-ACLR who take low daily steps will demonstrate deconditioned, less resilient cartilage characterized by poor tibiofemoral cartilage composition and greater cartilage strain which represent equally important, but independent measures of cartilage health. Furthermore, increasing daily steps using a 16-week daily step promotion paradigm in individuals post-ACLR who underload (\<7000 daily steps which is predictive of physical inactivity) will recondition cartilage by improving tibiofemoral cartilage composition and strain. The proposed study aims to determine: 1) associations between daily steps with tibiofemoral cartilage composition and strain in ACLR individuals (n=56) using an observational cross-sectional study design, and 2) the effects of increasing daily steps over 16-weeks on tibiofemoral cartilage composition and strain in ACLR individuals with low daily steps (n=28) using a single arm, longitudinal pre-test post-test study design. The proposed study is innovative because it builds on observational studies linking underloading with poor knee joint health and will be the first study to mechanistically determine how altering loading frequency (i.e., increasing daily steps) affects comprehensive in vivo measures of cartilage health in individuals at risk for OA. Successful completion of the proposed study will provide foundational evidence for the development of a future randomized controlled trial to determine the efficacy of an adaptive daily step promotion.
BACKGROUND: Many individuals who have olfactory dysfunction are not aware of their impairment, which results in delayed detection of potentially hazardous situations. Simple and accurate methods for objectively assessing olfactory function are needed. In this study, we aim to investigate the utility of serum neurofilament light chain (NfL) levels as an indicator of olfactory dysfunction.
METHODOLOGY: We analysed data on 1290 participants aged 40 years and older, who had valid data on olfaction and NfL level from the National Health and Nutrition Examination Survey 2013â€"2014. Multivariable modeling was used to investigate the relationship between olfactory dysfunction and NfL.
RESULTS: Among 1290 participants, 174 participants had olfactory dysfunction based on the results of the NHANES Pocket Smell Test. In ordinal regression models, objective olfactory dysfunction was associated with NfL. After adjusting for age, sex, race/ethnicity, diabetes, smoking, olfaction-related medical history, Parkinson's disease and Alzheimer's disease, the association remained significant. In logistic regression models, compared to participants with lower levels of NfL in the first tertile, those in the second and third tertiles had higher odds of objective olfactory dysfunction. There was no association between self-reported olfactory dysfunction and NfL tertiles.
CONCLUSIONS: A strong association between objective olfactory dysfunction and serum NfL level was observed. NfL, independent of age, is a reliable marker indicating the development of olfactory dysfunction. The measurement of serum NfL level provides valuable support for assessment of olfactory dysfunction in clinical practice.
We describe an elderly patient presenting with pneumothorax, cystic lung disease and a scalp lesion. The pneumothorax resolved after placing a chest tube and suction but recurred within a week. Progression of cystic features was also seen, and biopsies of the lung and scalp lesions were performed. Immunohistochemistry was positive for markers of endothelial cells (CD31 and ERG) and negative for markers expected to be positive in alveolar cells (keratin AE1/AE3 and TTF-1), supporting the diagnosis of metastatic angiosarcoma. Palliative chemotherapy did not prevent progression and the patient expired soon after. In describing the clinico-radiological correlation of metastatic angiosarcoma, we also briefly describe the approach to cystic lung disease. Understanding the pathophysiology of cyst formation in metastatic angiosarcoma may help clinicians to better appreciate and manage the full spectrum of cystic lung disease, especially with atypical features.
Novel thienopyridones with antihypertensive activity have the formula I,   <IMAGE> I  wherein the ring A represents an optionally substituted thiophene ring; m is 0 or 1; n is 0, 1 or 2; R is lower alkyl and R1 is lower alkyl. The fused thieno-ring may carry one or two substituents. Formula I encompasses thieno[3,2-b]pyridones, thieno[3,4-b]pyridones and thieno[2,3-b]pyridones. Processes for preparing the novel thienopyridones and pharmaceutical compositions containing them are described. Pharmaceutically acceptable acid addition salts of the compounds of formula I are also described. The thienopyridones of formula I are antihypertensive agents and are also indicated for use in treating heart failure and ischaemic heart disease.
PURPOSE: A composition for preventing or treating taurine chloramine (TauCl) is provided to suppress the differentiation of adipocytes and to regulate the expression of secretory materials in adipocytes, thereby effectively preventing or treating obesity. CONSTITUTION: A composition for preventing or treating obesity contains TauCl. TauCl suppresses the differentiation of preadipocytes into adipocytes. A food composition for preventing or treating obesity contains TauCl. A quasi-drug composition for preventing or treating obesity contains TauCl. A composition for suppressing differentiation into adipocytes contains TauCl.
PURPOSE:To obtain a preventive for cancer not causing side effects at all even by long-term administration, comprising essence of crude drug extracted from Glechoma hederacea L. as an active ingredient. CONSTITUTION:5-45 pts.wt., especially 13a-17 pts.wt. Glechoma hederacea L. (name of crude drug: Glechoma herba) and 130-1,200 pts.wt., especially 350-450 pts.wt. water are heated and boiled. The oozed solution is evaporated and concentrated until the amount of water of the oozed solution is halved while percolating the active ingredient of the crude drug in hot water to give essence of crude drug. A preventive for cancer is prepared in the form of the concentrated solution itself containing the essence of crude drug or in the form of liquor, powder, granule, pill or tablet. Various diseases showing cancer-like symptoms and having suspicion of cancer or transition of various affected parts in a prodromal stage of cancer are not only prevented by the preventive but also these diseases and affected parts can be completely cured or eliminated.
Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.